According to Summit Therapeutics
's latest financial reports the company has NZ$0.84 Billion in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | NZ$0.29 B | -46.36% |
2022-12-31 | NZ$0.54 B | 422.41% |
2021-12-31 | NZ$0.10 B | 14.18% |
2020-12-31 | NZ$92.04 M | |
2019-01-31 | NZ$66.96 M | 22.03% |
2018-01-31 | NZ$54.87 M | -8.69% |
2017-01-31 | NZ$60.1 M | 17.82% |
2016-01-31 | NZ$51.01 M | 44.98% |
2015-01-31 | NZ$35.18 M | 420.72% |
2014-01-31 | NZ$6.75 M | -32.99% |
2013-01-31 | NZ$10.08 M | 61.36% |
2012-01-31 | NZ$6.24 M | -40.93% |
2011-01-31 | NZ$10.58 M | -52.1% |
2010-01-31 | NZ$22.08 M | 103.03% |
2009-01-31 | NZ$10.87 M | -78.54% |
2008-01-31 | NZ$50.7 M | -50.36% |
2007-01-31 | NZ$0.10 B | 74.75% |
2006-01-31 | NZ$58.44 M | -17.09% |
2005-01-31 | NZ$70.49 M |